← Back to Clinical Trials
Recruiting NCT04971954

NCT04971954 Using Nicotine to Reverse Age-related Auditory Processing Deficits

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04971954
Status Recruiting
Phase
Sponsor University of California, Irvine
Condition Auditory Perceptual Impairment
Study Type INTERVENTIONAL
Enrollment 48 participants
Start Date 2022-02-01
Primary Completion 2026-06-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 85 Years
Study Type INTERVENTIONAL
Interventions
Nicotine gumPlacebo gum

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 48 participants in total. It began in 2022-02-01 with a primary completion date of 2026-06-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The present study will evaluate the effects of both aging and nicotine on psychophysical tasks and electrophysiological measures. Nicotine will be administered to study participants in the form of gum that is available as an over-the-counter medication. The hypothesis is that nicotine will reverse the detrimental effects of aging on auditory processing. The proposed experiments will characterize the effects of nicotine and may eventually lead to improved treatments of hearing loss in a variety of patient populations and in healthy aging.

Eligibility Criteria

Inclusion Criteria: * between 18 and 85 years of age * non-smokers with a score of 0-2 out of 10 maximum on the Fagerström index of smoking dependency * cognitive performance within two standard deviations of the CERAD mean Exclusion Criteria: * less than 18 or greater than 85 years of age * deafness or excessive hearing loss * smokers with a score between 3 and 10 on the Fagerström index of smoking dependency * history of psychiatric illness, neurological disorders, diabetes mellitus, renal failure, or cardiovascular disease * regular use of prescription medications (excluding oral contraceptives) * drug dependency

Contact & Investigator

Central Contact

Fan-Gang Zeng

✉ fzeng@uci.edu

📞 9498249107

Principal Investigator

Fan-Gang Zeng, PhD

PRINCIPAL INVESTIGATOR

University of California, Irvine

Frequently Asked Questions

Who can join the NCT04971954 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Auditory Perceptual Impairment. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04971954 currently recruiting?

Yes, NCT04971954 is actively recruiting participants. Contact the research team at fzeng@uci.edu for enrollment information.

Where is the NCT04971954 trial being conducted?

This trial is being conducted at Irvine, United States.

Who is sponsoring the NCT04971954 clinical trial?

NCT04971954 is sponsored by University of California, Irvine. The principal investigator is Fan-Gang Zeng, PhD at University of California, Irvine. The trial plans to enroll 48 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology